Khanh Pham Huyen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Khanh Pham Huyen has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Hoa Binh Nguyen
Vietnam National Lung Hospital, Hanoi 10000, Vietnam
2 shared publications - Bui Thi Tu Quyen
Department of Epidemiology and Biostatistics, The Hanoi School of Public Health, Hanoi, Vietnam
1 shared publication - Cornelia Hennig
World Health Organization (WHO), VietNam Country Office, Hanoi, Vietnam
1 shared publication - Cuong Le Xuan
National Hue hospital, Hue, Vietnam
1 shared publication - Hai Nguyen Viet
Vietnam Integrated Center for Tuberculosis and Respirology Research, Vietnam National Lung Hospital, Vietnam Tuberculosis Control Programme, Hanoi 100000, Vietnam
1 shared publication - Hanh Chu Thi
Bach Mai Hospital, Hanoi, Vietnam
1 shared publication
Latest Publications
- Open Access
- 22 December 2015
- Published by Springer Nature in BMC Research Notes
- Vol. 8 (1) , 1-6
Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam
Treatment outcomes of a high proportion of inpatients with multi-drug resistant tuberculosis (MDR-TB) were not reported to the Vietnamese National Tuberculosis Program because they received treatment outside of the green light committee (GLC) program. The study aimed (1) to describe the strengths and weaknesses of treatment of GLC and non-GLC MDR-TB patients as well as the factors influencing treatment completion and (2) to determine the incidence of adverse drug reactions. This cross-sectional study comprised two elements: (1) in-depth interviews with clinical doctors, hospital pharmacists; and focus group discussions with MDR-TB patients; and (2) a review of the charts of all GLC and non-GLC MDR-TB patients in 2010. A total of 282 MDR-TB patients were recruited, including 79(28 %) MDR-TB patients treated through the GLC program and 203(72 %) MDR-TB patients treated outside of the GLC program. The main strengths of GLC treatment were the supply of quality assured second line TB drugs, routine monitoring and clinical evaluation, free diagnostic tests and close clinical monitoring. The greatest barriers to patients treated outside of the GLC program was difficulty paying for second line TB drugs and other treatment costs. There was no significant difference between the incidence of adverse events among GLC (46.8 %) and non-GLC treated patients (52.2 %; p = 0.417). Among 143 patients who reported 226 adverse reaction events, arthralgia/joint pain (35.8 %), gastrointestinal (14.2 %), ototoxicity (8.4 %), cutaneous (6.6 %), and giddiness (5.8 %) were the most common. The non-GLC MDR-TB patients face substantial barriers to treatment, and require greater support if they are to complete treatment and improve disease outcomes. Staff training about the management of adverse drug reactions is needed.
- 22 December 2015
- Published by Springer Nature in BMC Research Notes
- Vol. 8 (1) , 1-6
Open AccessAdverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam
Treatment outcomes of a high proportion of inpatients with multi-drug resistant tuberculosis (MDR-TB) were not reported to the Vietnamese National Tuberculosis Program because they received treatment outside of the green light committee (GLC) program. The study aimed (1) to describe the strengths and weaknesses of treatment of GLC and non-GLC MDR-TB patients as well as the factors influencing treatment completion and (2) to determine the incidence of adverse drug reactions. This cross-sectional study comprised two elements: (1) in-depth interviews with clinical doctors, hospital pharmacists; and focus group discussions with MDR-TB patients; and (2) a review of the charts of all GLC and non-GLC MDR-TB patients in 2010. A total of 282 MDR-TB patients were recruited, including 79(28 %) MDR-TB patients treated through the GLC program and 203(72 %) MDR-TB patients treated outside of the GLC program. The main strengths of GLC treatment were the supply of quality assured second line TB drugs, routine monitoring and clinical evaluation, free diagnostic tests and close clinical monitoring. The greatest barriers to patients treated outside of the GLC program was difficulty paying for second line TB drugs and other treatment costs. There was no significant difference between the incidence of adverse events among GLC (46.8 %) and non-GLC treated patients (52.2 %; p = 0.417). Among 143 patients who reported 226 adverse reaction events, arthralgia/joint pain (35.8 %), gastrointestinal (14.2 %), ototoxicity (8.4 %), cutaneous (6.6 %), and giddiness (5.8 %) were the most common. The non-GLC MDR-TB patients face substantial barriers to treatment, and require greater support if they are to complete treatment and improve disease outcomes. Staff training about the management of adverse drug reactions is needed.
- Open Access
- 19 September 2012
- Published by Springer Nature in BMC Public Health
- Vol. 12 (1) , 808
A descriptive study of TB cases finding practices in the three largest public general hospitals in Vietnam
A project was implemented in 2010 to improve TB notification and TB screening and diagnostic routines in large general hospitals. The aims of present study was to assess baseline TB screening and diagnostic practices in the three largest general hospitals in Vietnam.
- 19 September 2012
- Published by Springer Nature in BMC Public Health
- Vol. 12 (1) , 808
Open AccessA descriptive study of TB cases finding practices in the three largest public general hospitals in Vietnam
A project was implemented in 2010 to improve TB notification and TB screening and diagnostic routines in large general hospitals. The aims of present study was to assess baseline TB screening and diagnostic practices in the three largest general hospitals in Vietnam.